Table 3.
Impact of the 12-gene assay per patient on average
| Description | Before 12-gene assay | After 12-gene assay | Difference |
|---|---|---|---|
| Use of adjuvant chemotherapy (%) | |||
| Fluoropyrimidine monotherapy | 24.1 | 12.8 | −11.3 |
| FOLFOX | 27.7 | 17.0 | −10.6 |
| Quality-adjusted survival | |||
| aCT related | −0.545 | −0.315 | 0.230 |
| Recurrence related | 8.546 | 8.430 | −0.117 |
| Total | 8.001 | 8.115 | 0.114 |
| Costs ($US) | |||
| 12-gene assay | 3,640 | 3,640 | |
| Acute aCT related | |||
| Drugs | 5,125 | 2,786 | −2,339 |
| Administration | 1,796 | 1,062 | −733 |
| Adverse events | 8,016 | 4,805 | −3,211 |
| Long term | 89,829 | 91,482 | 1,653 |
| Total | 104,767 | 103,775 | −991 |
All costs reported in $US, year 2014 values
aCT adjuvant chemotherapy, FOLFOX 5-fluorouracil and leucovorin, and oxaliplatin